Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sze, G.
Right arrow Articles by Weinreb, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sze, G.
Right arrow Articles by Weinreb, J. C.

Radiology, Vol 181, 693-699, Copyright © 1991 by Radiological Society of North America

ARTICLES

Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine

G Sze, M Brant-Zawadzki, VM Haughton, KR Maravilla, MT McNamara, AJ Kumar, AM Aisen, JN Dreisbach, WG Bradley Jr and JC Weinreb
Department of Diagnostic Imaging, Yale University Medical School, New Haven, CT 06510.

To evaluate the safety and efficacy of gadodiamide injection, a nonionic gadolinium chelate complex, in magnetic resonance (MR) imaging of the head and spine, a phase II-III trial was conducted in 439 patients with known or suspected lesions in the central nervous system. All patients received gadodiamide injection in a dosage of 0.1 mmol/kg and were monitored; MR images were evaluated for contrast material enhancement. No serious adverse events or clinically important trends in vital signs, laboratory values, or neurologic status were observed. Gadodiamide injection enhanced or facilitated the visualization of lesions in 266 or 353 patients (75.4%) in whom lesions were shown on unenhanced images, enhanced images, or both; in these 266 patients, the diagnosis was changed in 76 patients (28.6%) and facilitated in 190 patients (71.4%). It is concluded that gadodiamide injection is safe and effective for MR imaging of the head and spine in patients with suspected abnormalities of the central nervous system.


This article has been cited by other articles:


Home page
 Br. J. Radiol.Home page
A Li, C S Wong, M K Wong, C M Lee, and M C Au Yeung
Acute adverse reactions to magnetic resonance contrast media - gadolinium chelates
Br. J. Radiol., May 1, 2006; 79(941): 368 - 371.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
V. M. Runge and L. Berlin
Allergic Reactions to Gadolinium Chelates
Am. J. Roentgenol., October 1, 2001; 177(4): 944 - 945.
[Full Text] [PDF]

Home page
 RadiologyHome page
S. A. Thurnher, A. Capelastegui, F. H. Del Olmo, R. F. Dondelinger, C. Gervás, A. G. Jassoy, P. Keto, C. Loewe, C. N. Ludman, L. Marti-Bonmati, et al.
Safety and Effectiveness of Single- versus Triple-Dose Gadodiamide Injection- enhanced MR Angiography of the Abdomen: A Phase III Double-Blind Multicenter Study
Radiology, April 1, 2001; 219(1): 137 - 146.
[Abstract] [Full Text]

Home page
 Am. J. Neuroradiol.Home page
J. Breslau, J. G. Jarvik, D. R. Haynor, W. T. Longstreth Jr, D. L. Kent, and K. R. Maravilla
MR Contrast Media in Neuroimaging: A Critical Review of the Literature
AJNR Am. J. Neuroradiol., April 1, 1999; 20(4): 670 - 675.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1991 by the Radiological Society of North America.